SALT INFORMATIONOlmesartan (30's) TYPICAL USAGE Essential hypertension. SIDE EFFECTS Dizziness, headache, abdominal pain, dyspepsia, diarrhoea, gastroenteritis, nausea, hypotension, peripheral oedema, haematuria, UTI, hyperkalaemia, hypertriglyceridemia, hyperuricaemia, elevated liver enzymes, facial edema, angioedema, and rhabdomyolysis. DRUG INTERACTION Concurrent use with ACE inhibitors, potassium-sparing diuretics, potassium salts, and drugs that may increase serum potassium (e.g. ciclosporin, eplerenone) may increase the risk of hyperkalaemia. Concomitant use with NSAIDs may decrease glomerular filtration synergistically; acute renal failure may occur. Increased serum concentrations of lithium and toxicity when used with angiotensin receptor antagonist have been reported; avoid concomitant use of lithium and Olmesartan medoxomil. MECHANISM OF ACTION Olmesartan medoxomil is an ester prodrug for olmesartan. It is hydrolysed to olmesartan during absorption from the GI tract. Olmesartan is a selective and competitive angiotensin II Type 1 (AT1) receptor antagonist and hence it blocks the vasocontrictor and aldosterone-secreting effects of angiotensin II.